|
A new intravenous formulation of VIG (IV-VIG) is being produced to support the treatment of adverse events that may result from smallpox vaccination. There is currently sufficient IV-VIG available through CDC to treat the expected number of adverse events that might occur in the proposed pre-event responder vaccination programs. Additional doses of the new intravenous VIG product (IV-VIG) will continue to be available in the future to support any larger scale emergency vaccination programs. The new IV-VIG has a low level of aggregated protein, allowing its use through the intravenous route.
|
IV-VIG is available from CDC under Investigational New Drug (IND) protocol that will have guidelines for dosage and administration. The CDC Clinical Consultation Team can be contacted through the Clinicians Information Hotline at 1-877-554-4625 for VIG requests to treat vaccine related adverse events.
|
